Tectonic Therapeutic, Inc.

Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company headquartered in Watertown, Massachusetts, dedicated to the discovery and development of therapeutic proteins and antibodies. The company's core mission is to modulate the activity of G-Protein Coupled Receptors (GPCRs), a critical class of drug targets, to address significant unmet medical needs where current therapeutic options are limited or nonexistent.

Leveraging its proprietary GEODe™ (GPCRs Engineered for Optimal Discovery) technology platform, Tectonic Therapeutic aims to overcome challenges in GPCR-targeted drug discovery and develop innovative biologic medicines. Its pipeline includes TX45, an Fc-relaxin fusion molecule in Phase 1a/1b and Phase 2 clinical trials for Group 2 Pulmonary Hypertension in Heart Failure with Preserved and Reduced Ejection Fraction. The company is also developing TX2100, a GPCR antagonist for Hereditary Hemorrhagic Telangiectasia, and other GPCR modulators for conditions like fibrosis.

Tectonic Therapeutic became a publicly traded company on June 21, 2024, following its merger with AVROBIO, Inc., with its shares now trading on the Nasdaq Global Market under the ticker symbol TECX. Recent developments include the appointment of Jessica Chutter to its Board of Directors in April 2026 and the announcement of positive topline data from the Phase 1b Part B clinical trial for TX45 in October 2025. The company is led by President and CEO Alise Reicin, M.D., and co-founded by Harvard Medical School scientists Timothy A. Springer and Andrew C. Kruse.